The drug, Journavx by Vertex Pharmaceuticals, blocks pain signals to the brain, making it nonaddictive. The Food and Drug ...

The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...

Welcoming back Finn Wolfhard as Mike Wheeler, Gaten Matarazzo as Dustin Henderson, Caleb McLaughlin as Lucas Sinclair, Noah ...

The FDA approved a pain drug designed to eliminate the risks associated with opioids -- the first new pharmaceutical approach ...

To report SUSPECTED ADVERSE REACTIONS, contact Zevra Therapeutics, Inc. at toll-free phone 1-844-600-2237 or FDA at 1‐800-FDA-1088 or .

As a pharmacist-health services researcher, Dr. Antoinette Coe studies how to improve medication use and safety. Some of her motivation comes from personal experiences as a caregiver and helping ...

Claudette Alexson carried a portrait of her son Vince as she walked down 5th Avenue in Regina for a recent procession to ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...

Bezuclastinib plus sunitinib showed favorable safety and efficacy in GIST, outperforming sunitinib alone in phase 3 Peak ...

Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of ...

Treatment with bezuclastinib plus Sutent led to safe and efficacious outcomes versus Sutent treatment alone in gastrointestinal stromal tumors.